Michael addition-based synthesis of lawsone-derived benzopyrans: antibacterial, CREST and ADMET studies Authors: Ananya Dash, Barsha Samanta, Sonali Priyadarshini Parida, Tapaswini Pati, Laxmipriya Dash, Bhabani Shankar Panda, Chita Ranjan Sahoo, Seetaram Mohapatra Published: 2026 ABSTRACT Using the Michael addition reaction, we have developed a simple and facile method for the synthesis of novel lawsone-based highly substituted benzopyrans in good to excellent yields (62–94%) at room temperature. All the synthesized compounds were characterized by 1H NMR, 13C NMR, FTIR and HRMS. The relative configuration was assigned by ROESY spectrum, showing 1,3-syn interaction between H1 and H3 protons and further supported by CREST analysis. The Structure-E having SSR configuration possesses the lowest relative electronic energy among the eight possible structures. Following this, the in vitro antibacterial activity was evaluated for the synthesized compounds against two bacterial strains, E. coli (PDB ID: 1KZN) and S. aureus (PDB ID: 3G75), using DNA gyrase as the target. Among the tested compounds, 3p with 6,8-dichloro and –OMe appended phenyl group exhibited the highest bacterial inhibition potency with an MIC value of 6.25 µg mL−1 against E. coli and 12.5 µg mL−1 against S. aureus respectively. Additionally, in silico molecular docking results also revealed that 3p has an excellent binding free-energy estimate of −9.3 kcal mol−1 and −8.2 kcal mol−1 against E. coli and S. aureus. As well, the synthesized compounds with promising pharmacokinetic and drug-like properties were established by ADMET investigations. Consequently, the results of in vitro and in silico assays discovered the capabilities of these compounds as active antibacterial drugs. Introduction Antimicrobial resistance (AMR) is a major global health challenge, disproportionately affecting low- and middle-income countries. According to the WHO, AMR is a “silent pandemic” and is associated with approximately 4.95 million deaths worldwide, with the burden projected to increase substantially by 2050 if left unaddressed. This growing burden underscores the urgent need for new antibacterial agents and structurally diverse therapeutic scaffolds.1 In this context, quinones have attracted considerable attention as promising bioactive scaffolds. Widely recognized for their applications as dyes in the chemical industry, quinones also represent a prominent class of biologically active molecules.2 The quinone moiety is a key structural unit found in numerous natural products that perform essential biological functions across a variety of organisms, including humans, animals, and plants.3 This structural motif has thus gained substantial attention in medicinal chemistry, leading to the development of a broad range of synthetic quinone-containing compounds with demonstrated anticancer,4 antimalarial,5 antifungal,6 and antibacterial properties7,8 among others. Within the diverse family of quinones, 2-hydroxy-1,4-naphthoquinone, commonly known as lawsone, has emerged as a particularly intriguing molecule due to its simple structure and rich pharmacological profile. Naturally sourced from the dried leaves of Lawsonia inermis (henna), lawsone has been traditionally used as a natural dye for centuries.9–11 Beyond its historical significance, lawsone has garnered increasing interest in modern medicinal chemistry owing to its chemical reactivity and therapeutic versatility. Its molecular architecture enables redox cycling via the quinonoid core and offers a reactive hydroxyl group that facilitates asymmetric transformations. Moreover, the C-3 position of lawsone is highly amenable to carbon–carbon bond formation, making it a valuable scaffold for the synthesis of structurally diverse bioactive molecules.12 A wide range of structurally diverse natural and synthetic derivatives of lawsone, including lapachol, nor-lapachol, dunniol, parvaquone, buparvaquone, lomatiol, and atovaquone have been reported, highlighting the synthetic versatility and biological importance of the lawsone scaffold (Fig. 1).13–18 The lawsone-based derivatives have been widely recognized for their potent antiparasitic and anticancer activities. In addition, numerous studies highlight their remarkable antibacterial potential. For instance, Ratti et al. demonstrated the antibacterial and antibiofilm efficacy of synthetic lawsone derivatives containing N-substituted 1,2,3-triazoles.19 Similarly, Song et al. reported diverse naphthoquinone derivatives capable of exhibiting activity against methicillin-resistant Staphylococcus aureus, while Anaikutti et al. identified 4H-chromene naphthoquinone derivatives as highly effective antibacterial agents.20 Selective & representative examples of biologically imperative natural products 1–7 possessing 2-hydroxy-1,4-naphthoquinone framework. In line with these developments, we recently reported a comprehensive review covering both the synthesis and biological activity of lawsone derivatives.21 Moreover, extensive literature has established lawsone as a highly versatile scaffold for heterocyclic synthesis.13,22–28 This remarkable molecular diversity, together with the significant biological relevance of lawsone-based architectures, underscores their value as key building blocks for developing structurally diverse heterocyclic frameworks. These include xanthenes, ylids, phenazines, quinoxalines, spiro-compounds, acridines, oxazines, anthracenes, furans, quinolones, and related systems.29 Furthermore, our research includes the construction of diverse fused and conjugated 3-nitro-2H-chromene derivatives, whose biological activities have been explored.30,31 Considering the synthetic importance and biological relevance of lawsone, we envisioned the design and synthesis of lawsone-based highly substituted benzopyran conjugates via Michael addition. The synthesized compounds were subsequently evaluated for their antibacterial potential through in vitro assays and in silico molecular docking. The relative configuration was assigned by ROESY spectra and further supported by CREST analysis. Additionally, the physicochemical and ADMET characteristics of the synthesized compounds were anticipated to ascertain their potential as oral antibacterial drugs. Based on the results, it is predicted that a strong foundation will be provided for future study and the development of lawsone-based benzopyran derivatives as efficient antibacterial agents. Results and discussion Chemistry The protocol began with synthesizing 2-phenyl-3-nitro-2H-chromene derivatives as starting materials, following previously reported methods.32 After obtaining the required 2-phenyl-3-nitro-2H-chromene derivatives, we proceeded with the synthesis of lawsone-based highly substituted benzopyrans. The chromene derivatives were reacted with 2-hydroxy-1,4-naphthoquinone via Michael addition. The reaction conditions were optimized by screening different bases, solvents and temperatures for compound 3a (Table 1). Table 1Optimization of the reaction conditions for the synthesis of lawsone-based highly substituted benzopyran derivatives EntrySolventBaseEquiv. of baseTemperature (°C)Time (h or min)Isolated yieldb (%)1EtOH——r.t.24 hn.r.2EtOHEt3N0.5r.t.1 h123DCMEt3N1r.t.2 h334DCMDABCO1r.t.3 h225DCMEt3N0.8r.t.45 min406TolueneEt3N0.8r.t.1 h83 7 a Toluene Et 3 N 1 r.t. 45 min 92 8TolueneEt3N18045 min349TolueneEt3N11101 h2310TolueneDABCO1802 h3711TolueneCs2CO31803 hn.r.12THFEt3N18012 hn.r.aStandard condition: 2-phenyl-3-nitro-2H-chromene (1a, 1.0 equiv.), 2-hydroxy-1,4-naphthoquinone (2, 1.0 equiv.), triethylamine (1.0 equiv.), time (45 min), toluene (3 mL), room temperature.bIsolated yield; n.r.: no reaction. Optimization of the reaction conditions for the synthesis of lawsone-based highly substituted benzopyran derivatives Standard condition: 2-phenyl-3-nitro-2H-chromene (1a, 1.0 equiv.), 2-hydroxy-1,4-naphthoquinone (2, 1.0 equiv.), triethylamine (1.0 equiv.), time (45 min), toluene (3 mL), room temperature. Isolated yield; n.r.: no reaction. Initially, 1.0 equivalent of 2-phenyl-3-nitro-2H-chromene and 1.0 equivalent of 2-hydroxy-1,4-naphthoquinone were mixed in ethanol. The reaction mixture was stirred at room temperature for 24 hours; however, no reaction was observed (Entry 1). Next, we added 0.5 equivalent of Et3N to the same solvent at room temperature for 1 hour, resulting in a low yield of 12% (Entry 2). Next, the solvent was changed to DCM and performed the reactions using different bases, including Et3N and DABCO. However, these conditions did not provide satisfactory yields (Entries 3–5). We than opted for toluene as the solvent and carried out the reaction using 0.8 equivalent of Et3N at ambient temperature for 1 hour, resulting in a satisfactory yield of 83% (Entry 6). Subsequently, we adjusted the Et3N amount to 1.0 equivalent and stirred the mixture for 45 minutes at room temperature, achieving an outstanding yield of 92% of the desired product (Entry 7). Then, we tested the reaction at 80 °C for 45 minutes and at 110 °C for 1 hour, but the yields were unsatisfactory (Entries 8 and 9). However, when DABCO was used as the base at 80 °C for 2 hours, a low yield of 37% was obtained (Entry 10). Additionally, using Cs2CO3 as the base with toluene as the solvent resulted in no reaction (Entry 11). Further, changing the solvent to aprotic THF with Et3N at 80 °C for 12 hours also failed to yield any reaction (Entry 12). After establishing the optimal reaction conditions, we explored the substrate scope by testing various 2-phenyl-3-nitro-2H-chromene derivatives 1a–r containing both electron-donating and electron-withdrawing groups. All 2-phenyl-3-nitro-2H-chromenes reacted efficiently with 2-hydroxynaphthoquinone 2, irrespective of the nature and position of the substituents. Eighteen desired Michael adducts 3a–r were obtained in good to excellent yields (Scheme 1). Synthesis of lawsone-based highly substituted benzopyran derivatives. Initially, the simple 2-phenyl-3-nitro-2H-chromene 1a performed a successful Michael addition with 2-hydroxy-1,4-naphthoquinone 2, yielding 92% of 3a. The benzopyran ring, featuring an electron-donating group such as –OMe at the C8 position, was readily accepted and produced the Michael adduct 3b with an excellent yield of 89%. However, compounds containing electron-withdrawing groups such as –Cl or –Br at the C6 or C8 positions showed reduced yields. Compounds 3c–3g were obtained in yields ranging from 69% to 77%. Next, the combined presence of an electron-donating –OMe and an electron-withdrawing –Br substituent on the chromene scaffold proved synergistic, as compound 3h was obtained in 88% yield. Subsequent modification of the 2-phenyl moiety revealed that chloro substitution on the para position exerted a deleterious effect on the transformation, as products 3i, 3j, 3k, 3l were isolated in diminished yields, with 3l, bearing multiple halogen substituents, giving the lowest yield of 62%. Conversely, incorporation of a methoxy group on the phenyl ring markedly enhanced the reaction efficiency. Hence, compound 3m, featuring –OMe substituents on both the chromene and phenyl rings, furnished the highest yield of 94%. Importantly, even in the presence of additional halogen substituents on the chromene framework, –OMe substituted phenyl derivatives remained highly competent substrates, providing compounds 3n to 3r in good to excellent yields (77–88%) (Fig. 2). Synthesis of a library of lawsone-based highly substituted benzopyrans 3a–r. The practical synthetic utility of this procedure was observed after testing different substrates for this Michael addition reaction. Under screening conditions, the gram-scale reaction between 8-methoxy-2-(4-methoxyphenyl)-3-nitro-2H-chromene (1m) and lawsone (2) was carried out. An isolated yield of 92% of the desired product was obtained (Scheme 2). Gram-scale synthesis. Besides this, when the reaction was conducted with other 2H-chromene based cyclic conjugates such as 2H-chromene-3-carbaldehyde and 2H-chromene-3-carbonitrile at the same optimum conditions, no distinct product was obtained (Scheme 3). As compared with 3-nitro-2H-chromenes, the chromene-3-carbaldehyde and chromene-3-carbonitrile derivatives are relatively weaker Michael acceptors under the reaction conditions. The strongly electron-withdrawing nitro group in 3-nitro-2H-chromenes substantially increases the electrophilicity of the β-carbon, thereby facilitating the Michael addition. In contrast, the aldehyde and nitrile substituents do not activate the chromene double bond to the same extent, resulting in insufficient electrophilic activation for efficient Michael addition. Limitations of our proposed reaction. Characterization The final compound 3a was characterized and confirmed using 1H NMR, 13C NMR, and HRMS spectra analysis. In the 1H NMR spectrum, compound 3a exhibited a sharp singlet at 5.96 ppm, corresponding to the H1 proton. Additionally, two more singlets appeared at 5.01 ppm and 5.68 ppm, assigned to H2 and H3 protons, supporting the 1,4-conjugate addition of lawsone to the nitrochromene scaffold. The remaining thirteen aromatic protons resonated within the 6.93–8.06 ppm range. In the 13C NMR spectrum, a notable peak was observed at 74.6 ppm, corresponding to C3 carbon, while C10 appeared at 135.9 ppm, indicating the formation of a C–C bond between the benzopyran ring and lawsone. Also, peaks for C1 and C2 carbons were identified at 87.5 ppm and 33.7 ppm, respectively. Furthermore, the 2-hydroxynaphthoquinone system, which contains two carbonyl carbons (C12 and C13), exhibited peaks at 183.7 ppm and 181.4 ppm, respectively. Other quaternary carbons, including C8, C9, C11, C18, C19, and C20, were detected with chemical shift values of 157.7 ppm, 132.2 ppm, 153.6 ppm, 130.2 ppm, 128.5 ppm, and 133.3 ppm, respectively. In the IR spectrum of 3a, two absorption bands were observed in the region of 1547 cm−1 and 1373 cm−1 confirming the presence of the NO2 group. Also, the carbonyl groups showed a sharp absorption band at 1644 cm−1. The HRMS analysis of compound 3a showed the experimental value of [M + H]+ at 428.1126 compared to the calculated value of 428.1180, which confirmed the formation of the final product 3a (Fig. 3). The relative configuration was assigned by ROESY. In the ROESY spectrum, the 1,3-interaction between the aliphatic protons H1 and H3 was observed which are syn to each other (Fig. 4). 1H and 13C NMR data analysis of compound 3a. 1,3-Interaction of compound 3a. Mechanism Mechanistically, triethylamine first deprotonates lawsone (2), generating a resonance-stabilized enolate species. This nucleophilic species then attacks the β-carbon of the electron-deficient nitroalkene (1a) through Michael addition reaction. Then, proton transfer gives the desired product compound 3a (Fig. 5). Plausible reaction pathway. CREST studies The ROESY analysis predicted the syn relationship between H1 and H3 protons. To validate this experimental finding and to identify the preferred configuration of the compound 3a, we have performed quantum chemical calculations. The structural optimization for eight probable configurations of the synthesized 2-hydroxy-(3-nitro-2-phenylchroman-4-yl)naphthalene-1,4-dione 3a, possessing three stereocenters, was performed using B3LYP/6-311++G(d,p) level of theory. However, there can be many possible conformers of each configuration and we can't directly comment on the stability of these configurations from a single optimized structure. Therefore, we have employed the Conformer Rotamer Ensemble Sampling Tool (CREST) to systematically analyse the lowest possible conformers of these possible eight structures on the potential energy surface. The compound 3a having three stereocenters gives rise to eight possible configurations such as RRS (Structure-A), RSS (Structure-B), SRS (Structure-C), RSR (Structure-D), SSR (Structure-E), SRR (Structure-F), RRR (Structure-G), SSS (Structure-H). All the possible conformers of these eight structures were derived using CREST and all those conformers were re-optimized using B3LYP/6-311++G(d,p) level of theory. The resulting lowest energy possible conformers of these structures are shown in Fig. 6. The relative electronic energies of all the conformers are summarized in Table 2. The Structure-E having SSR configuration possesses the lowest energy among all of them in which H1 and H3 protons are syn to each other which is again in accordance with the ROESY study (Fig. 7). The lowest possible conformers of eight probable structures of the compound 3a (A–H) calculated using DFT/B3LYP/6-311++G(d,p) level of theory. The relative energies of all the conformers (obtained from CREST analysis) of the possible eight structures Structure-AΔEel (kcal mol−1)Structure-BΔEel (kcal mol−1)Structure-CΔEel (kcal mol−1)Structure-DΔEel (kcal mol−1)Conformer-15.79Conformer-17.49Conformer-13.15Conformer-13.15Conformer-20.01Conformer-214.73Conformer-23.18Conformer-23.18Conformer-30.26Conformer-314.73Conformer-36.08Conformer-36.08Conformer-47.89Conformer-414.73Conformer-47.90Conformer-47.90Conformer-57.89Conformer-57.17Conformer-59.74Conformer-59.74Conformer-69.79Conformer-67.49Conformer-68.74Conformer-68.74——Conformer-717.44——————Conformer-818.86———— Structure-EΔEel (kcal mol−1)Structure-FΔEel (kcal mol−1)Structure-GΔEel (kcal mol−1)Structure-HΔEel (kcal mol−1)Conformer-15.79Conformer-15.13Conformer-13.61Conformer-13.61Conformer-20Conformer-213.01Conformer-23.77Conformer-23.77Conformer-30.26Conformer-313.02Conformer-39.14Conformer-33.77Conformer-47.89Conformer-47.49—Conformer-43.31Conformer-57.89Conformer-514.73———Conformer-614.73———Conformer-714.73———Conformer-87.49— Eight probable structures (A–H) of the compound 3a. Biological evaluation Antibacterial screening The antibacterial efficacy of the synthesized compounds was assessed against Escherichia coli (Gram-negative) MTCC 614 and Staphylococcus aureus (Gram-positive) MTCC 7443 using Zone of Inhibition (ZI) (Fig. 8) and minimum inhibitory concentration (MIC) (Fig. 9) as key parameters. Among all tested compounds, 3p displayed the highest antibacterial activity, with a ZI of 19 mm against E. coli and 17 mm against S. aureus. It also exhibited the lowest MIC values, measuring 6.25 µg mL−1 for E. coli and 12.5 µg mL−1 for S. aureus, demonstrating potency comparable to ciprofloxacin (ZI = 20 mm, MIC = 6.25 µg mL−1 for E. coli and ZI = 18 mm, MIC = 12.5 µg mL−1 for S. aureus). Several other compounds, notably 3g, 3l, 3n and 3o also demonstrated significant antibacterial activity. These compounds showed ZI values ≥ 17 mm and MIC values ≤ 25 µg mL−1 against both bacterial strains. A notable trend observed was that Gram-negative E. coli appeared to be more susceptible to these compounds than Gram-positive S. aureus, likely due to structural differences in their cell walls. Conversely, compounds exhibiting lower ZI values, such as 3b and 3m, showed weaker antibacterial activity, with MIC values reaching up to 100 µg mL−1. These findings suggest that the antibacterial potency of the synthesized compounds is influenced by specific structural features. Comparison of ZI (in mm) values of the tested compounds with that of the standard drug ciprofloxacin. Comparison of MIC (in µg mL−1) values of the tested compounds with that of the standard drug ciprofloxacin. Molecular docking studies The antibacterial assays establish the whole-cell antibacterial activity of the synthesized compounds 3a–r, whereas the molecular docking studies provide a computational assessment of their potential interactions with bacterial DNA gyrase. The docking results therefore represent a hypothesis regarding a possible molecular target and establish DNA-gyrase inhibition as the mechanism responsible for the observed antibacterial activity. To understand the molecular mechanism of antibacterial activity, docking studies were performed against E. coli DNA gyrase (PDB ID: 1KZN) and S. aureus DNA gyrase (PDB ID: 3G75) (Table 3). PDB IDs 1KZN and 3G75 were selected because these represent experimentally determined ligand-bound structures of the GyrB ATPase domain from E. coli and S. aureus, respectively. The 1KZN structure contains the co-crystallized coumarin inhibitor clorobiocin, whereas 3G75 contains the pyrazol-thiazole inhibitor B48. The corresponding ligand-binding regions were therefore considered pharmacologically relevant reference pockets for evaluating the predicted interactions of the synthesized compounds. The results showed that compound 3p had the highest binding affinity, with docking scores of −9.3 for E. coli and −8.2 for S. aureus, indicating strong interaction with the active site of the target enzymes. This correlates well with its superior antibacterial activity. Similarly, compounds 3g, 3i, 3l, 3n, and 3o exhibited strong binding affinities, with docking scores ranging from −8.3 to −9.1 for E. coli and −7.1 to −8.1 for S. aureus. These findings support their potent antibacterial effects observed in vitro. In contrast, the least active compounds, such as compound 3b and compound 3m, had lower docking scores (−7.3 to −5.8), suggesting weaker interactions with DNA gyrase, which is consistent with their reduced antibacterial activity. The docking interactions of compounds 3p and 3n with DNA gyrase from E. coli (PDB ID: 1KZN) and S. aureus (PDB ID: 3G75), respectively, are shown in Fig. 10 and 11. Both 2D and 3D interaction modes are presented. Table 3Molecular docking scores and the binding intercation of the compounds 3a–rSl. no. E. coli (PDB ID: 1KZN) S. aureus (PDB ID: 3G75)Score (kcal mol−1)Binding interactionsScore (kcal mol−1)Binding interactions3a−7.9ARG62, GLU36, ILE76, ILE64, ALA39−6.4SER82, ILE79, SER83, VAL853b−7.3ARG62, ASP35, ILE76, VAL87, ILE64−6.2ARG61, GLU35, ILE63, GLY62, PRO643c−7.9GLU36, ARG62, ILE76, ILE64, ALA39−7.2ASP34, PRO64, THR127, ASN31, ALA38, ILE633d−7.9GLU36, ASN32, ARG62, ILE76, PRO65−6.4GLU27, ASN31, SER83, ILE79, ILE633e−7.8GLU36, ASN32, ILE64, PRO65−7.0ASN31, ILE79, PRO64, ILE633f−8.4GLU36, GLY63, THR132, ASN32, ALA72, ILE76, PRO65, ALA 39, ILE64−6.9ASN31, GLU35, ILE79, PRO64, ILE633g−9.0GLU36, GLY63, THR132, ASN32, PRO65, ALA39, ILE64, ILE76−7.1GLU35, GLY62, ILE79, PRO64, ILE633h−7.5GLU36, ASN32, GLY63, PRO65, ILE64, ILE76−8.1ASN31, ARG61, GLY62, GLU35, PRO64, ILE633i−8.3ARG62, GLU36, VAL134, ALA33, ALA39, ILE64, ILE76−7.7GLU35, ASN31, ILE28, ILE129, VAL56, PRO64, ILE63, ILE793j−8.2ARG62, GLU36, ASN32, ALA72, ILE76, PRO65, ILE64−6.9GLU35, ALA38, PRO64, ILE633k−8.5GLU36, ASN32, ALA33, PRO65, ILE64−7.1ASN31, ILE79, PRO64, ILE633l−8.9GLU36, THR132, GLY63, PRO65, ASN32, LEU38, ILE64, ILE76, ALA39−7.1THR127, ILE79, PRO64, ILE633m−7.1ARG62, ASN32, GLU36, GLY63, VAL87, ILE64−5.8GLU35, ASN31, PRO64, ILE63, ILE793n −9.1 ARG103, ASN32, ARG62, ILE64, VAL87, PRO65 −8.1 ARG61, GLU35, ASP58, THR127, PRO64, GLY62, ILE63 3o−8.7ARG62, ASP59, PRO65, ALA33, ILE64−7.3ARG61, GLU35, SER32, ILE63, PRO64, VAL56, ILE28, ILE129, ILE793p −9.3 ASP59, GLU36, ARG62, GLY63, ARG103, LEU38, ALA72, ILE76, ALA39, PRO65, ILE64 −8.2 ASN31, PRO64, ARG61, LEU37, ILE79, ILE63, ALA38 3q−8.4GLU36, ASN32, ASP59, ILE64, ILE76, ALA33, VAL87, PRO65−7.9ASN31, ARG61, THR127, ILE63, GLY62, ALA38, PRO643r−7.5GLU36, ARG62, ASN32, PRO65, ILE76, ILE64−7.6THR127, GLU35, ARG61, ASN31, PRO64, GLY62, ILE28, ILE129, ILE63Cipro-floxacin−7.8ILE76, ILE64, VAL87, VAL134, ASN32, THR132, ASP59−7.6SER32, ILE79, ILE63, PRO64, GLY62, GLU35, THR127 Molecular docking scores and the binding intercation of the compounds 3a–r 2D (A and C) and 3D (B and D) representations of the docking interactions of compound 3p with E. coli DNA gyrase (PDB ID: 3 G7E) and S. aureus DNA gyrase (PDB ID: 357B), respectively. Compound 3p is depicted as a stick model, and the interacting amino-acid residues are labelled. The 2D representations show the major hydrogen-bonding, π-, alkyl, and other non-covalent interactions, while the 3D views illustrate the binding pose of 3p in the active sites. 2D (A and C) and 3D (B and D) representations of the docking interactions of compound 3n with E. coli DNA gyrase (PDB ID: 3 G7E) and S. aureus DNA gyrase (PDB ID: 357B), respectively. Compound 3n is depicted as a stick model, and the interacting amino-acid residues are labelled. The 2D representations show the major hydrogen-bonding, π-, alkyl, and other non-covalent interactions, while the 3D views illustrate the binding pose of 3n in the active sites. Structure–activity relationships The antibacterial screening and molecular docking results of the synthesized compounds 3a–r offer clear insights into their structure–activity relationships (SARs) analysis (Fig. 12). The SARs analysis results revealed a distinct dependence of antibacterial potency on the substitution pattern of the benzopyran and phenyl moieties. Compound 3p, bearing chlorine substituents at the C6 and C8 positions of the benzopyran ring along with an attached p-OMe phenyl group, demonstrated the most potent antibacterial activity, with MIC values of 6.25 µg mL−1 against E. coli and 12.5 µg mL−1 against S. aureus. Computational docking analysis further supported its efficacy, revealing favourable binding interactions with DNA gyrase from both Gram-negative (E. coli, −9.3 kcal mol−1) and Gram-positive (S. aureus, −8.2 kcal mol−1) proteins. Compound 3n, featuring a C6-chloro substitution and an attached –OMe group in the phenyl moiety, also showed significant activity, exhibiting MIC values of 12.5 and 25 µg mL−1 against E. coli and S. aureus respectively. In contrast, compounds 3m and 3b, which possess an electron-donating –OMe group at C8 position, showed comparatively poor antibacterial activity and less favourable docking scores. Pictorial illustration of SARs of lawsone-based highly substituted benzopyran derivatives 3a–r from antibacterial evaluation and molecular docking study. To further support the proposed SARs, the docking scores of all derivatives 3a–r were systematically compared with their corresponding experimental MIC values against E. coli and S. aureus (Table 4). Overall, the docking scores showed an association with the experimental MIC values, with more favorable (more negative) docking scores generally corresponding to lower MIC values. Table 4Comparison of experimental MIC values and docking scores of compounds 3a–rCompound E. coli S. aureus MIC (µg mL−1)Docking score (kcal mol−1)MIC (µg mL−1)Docking score (kcal mol−1)3a50−7.9100−6.43b100−7.3100−6.23c50−7.950−7.23d50−7.9100−6.43e50−7.850−7.03f25−8.450−6.93g25−9.025−7.13h100−7.525−8.13i25−8.350−7.73j50−8.2100−6.93k50−8.550−7.13l25−8.950−7.13m50−7.1100−5.83n12.5−9.125−8.13o25−8.725−7.33p6.25−9.312.5−8.23q50−8.425−7.93r100−7.550−7.6 Comparison of experimental MIC values and docking scores of compounds 3a–r In silico ADMET studies In silico ADMET analysis was integrated with our experimental assays to better interpret the screening results to provide a preliminary computational assessment of the physicochemical, pharmacokinetic and toxicity-related properties of the selected compounds.33 These computational analyses provide rapid and cost-effective estimates of absorption, distribution, metabolism, excretion and potential toxicity parameters that may be useful for prioritizing promising compounds for further investigation. However, the predicted parameters are model-dependent and should not be considered as experimentally established pharmacokinetic or toxicological properties. In particular, computational drug-likeness and ADMET predictions alone cannot establish oral bioavailability, pharmacokinetic suitability, or suitability for oral drug development. Physicochemical and medicinal chemistry property prediction Predictions of key physicochemical and medicinal chemistry properties of the synthesized compounds are crucial for understanding their drug-like behavior. Calculated parameters, such as lipophilicity, topological polar surface area, molecular flexibility, and hydrogen-bonding capacity, were consistent with the structural features observed across the series. These parameters suggested that the compounds possess favourable predicted drug-like physicochemical characteristics.34,35 These predictions also helped rationalize differences in biological activity by highlighting how subtle variations in polarity and molecular size may influence permeability or target engagement. Lipinski's rule, Veber's rule, Egan's rule and Golden Triangle rule are some important drug-likeness rules widely used to determine the oral activity of drugs before clinical trials. Lipinski's rule of five suggests that a candidate molecule is more likely to exhibit oral activity if it meets the following criteria: (a) MW ≤ 500 g mol−1, (b) log P ≤ 4.15, (c) nHD ≤ 5, (d) nHA ≤ 10, and (e) no more than one of these criteria is violated34,36 The Veber's rule states that, a molecule is more likely to be orally active if: (a) nRB ≤ 10 and (b) TPSA ≤ 140 Å2. According to Egan's rule, a candidate molecule is more likely to be orally active if: (a) log P ≤ 5.88 and (b) TPSA is ≤ 131.6 Å2.33 Similarly, the Golden Triangle rule further suggests that favorable oral drug-like properties are associated with: (a) MW between 200 to 500 g mol−1 and (b) log D between −2 to 3.37 The predicted physicochemical and medicinal chemistry properties of the two potent antibacterial compounds, 3p and 3n, and standard drug ciprofloxacin are as shown in Table 5. The results showed that both the potent compounds possess a total polar surface area (TPSA) below 140 Å2 and no more than 11 rotatable bonds suggesting a potentially favourable predicted oral absorption profile.34,38 The molecular weights, the number of hydrogen bond acceptors and the number of hydrogen bond donors of selected compounds were found within the recommended limit. The absorption rates of the two potent compounds and standard drug were calculated by an empirical TPSA-based theoretical formula (% ABS = 109 − (0.345 × TPSA)).33 The computational predictions of these compounds suggested moderate to favourable absorption-related characteristics, along with 128.39 to 133.40 m3 mol−1 molar refractivity and oral absorption percentages more than 50%. Moreover, the predicted physicochemical properties indicated that nearly all the properties of both potent compounds 3p and 3n aligned well with the lower and upper optimal reference values, as depicted in their radar plots (Fig. 13). These potent compounds exhibited good synthetic accessibility scores, bioavailability scores, pan assay interference structures, medicinal chemistry evolution, drug-likeness model scores and promiscuous compound scores in comparison with the standard drug. Overall, the computational prediction scores suggested that both the potent compounds 3p and 3n nearly followed the four drug likeness rules (Lipinski's rule, Veber's rule, Egan's rule and Golden Triangle rule), whereas the standard drug ciprofloxacin satisfied only Golden Triangle rule. Table 5Physicochemical properties, medicinal chemistry properties and physicochemical properties-based drug likeness rules, bioavailability score and drug-likeness model score of two potent compounds 3p, 3n and standard drug ciprofloxacinaPropertiesCompoundsRecommended limit3p3nCiprofloxacin Physicochemical MW526.32491.88331.13100 to 600 g mol−1 n HA7760 to 12 n HD1120 to 7 n Ring5540 to 6 fChar000−4 to 4 n Het10971 to 15 n Rig3131220 to 30 MaxRing1010100 to 18log D3.243.131.141 to 3log S−5.29−5.08−1.17−4 to 0.5 mol L−1log P4.624.11−0.10 to 5 log octanol/waterCsp30.150.150.41≥0.42MR133.40128.3995.2540 to 130 m3 mol−1TPSA (Å2)118.65118.6574.570 to 140 Å2 n RB4430 to 11% ABS68.07%68.07%83.27%>50% Medicinal chemistry PAINS1100 alertsMCE-1899.29656.83≥45SA score332.51≤6NP score0.110.15−0.73−5 to 5PC score0.020.020.39≈0BA score0.560.560.55≥0.5DM score0.700.790.84≥0.5 Drug likeness rules Lipinski's ruleAccepted (1 violation: MW > 500)AcceptedAcceptedMW ≤ 500, log P ≤ 5, nHA ≤ 10, nHD ≤ 5, nVio ≤ 1Veber's ruleAcceptedAcceptedAccepted n RB ≤ 10, TPSA ≤ 140 Å2Egan's ruleAcceptedAcceptedAcceptedlog P ≤ 5.88, TPSA ≤ 131.6 Å2Golden Triangle ruleRejected (1 violation: MW > 500)AcceptedAccepted200 ≤ MW ≤ 500, −2 ≤ log D ≤ 3aMW = molecular weight (in g mol−1), nRB = number of rotatable bonds, nHA = number of hydrogen bond acceptors, nHD = number of hydrogen bond donors, log P = the logarithm of the n-octanol/water distribution coefficients at 7.4 pH, TPSA = topological polar surface area (in Å2), Csp3 = sp3 hybridized fraction of carbon atoms in a molecule, MR = molar refractivity (m3 mol−1), log S = the logarithm of aqueous solubility value, % ABS = TPSA-based estimated percentage absorption calculated using % ABS = 109 − (0.345 × TPSA), SA score = synthetic accessibility score, BA score = bioavailability score, PAINS = pan assay interference structures, MCE-18 = medicinal chemistry evolution, DM score = drug-likeness model score, PC score = promiscuous compound score, nVio = the number of violations. Physicochemical properties, medicinal chemistry properties and physicochemical properties-based drug likeness rules, bioavailability score and drug-likeness model score of two potent compounds 3p, 3n and standard drug ciprofloxacina MW = molecular weight (in g mol−1), nRB = number of rotatable bonds, nHA = number of hydrogen bond acceptors, nHD = number of hydrogen bond donors, log P = the logarithm of the n-octanol/water distribution coefficients at 7.4 pH, TPSA = topological polar surface area (in Å2), Csp3 = sp3 hybridized fraction of carbon atoms in a molecule, MR = molar refractivity (m3 mol−1), log S = the logarithm of aqueous solubility value, % ABS = TPSA-based estimated percentage absorption calculated using % ABS = 109 − (0.345 × TPSA), SA score = synthetic accessibility score, BA score = bioavailability score, PAINS = pan assay interference structures, MCE-18 = medicinal chemistry evolution, DM score = drug-likeness model score, PC score = promiscuous compound score, nVio = the number of violations. Radar chart of the physicochemical properties of the two potent compounds 3p, 3n and standard antibacterial drug ciprofloxacin showing the in silico measurements of the descriptors MW, nRig, fChar, nHet, MaxRig, nRing, nRot, TPSA, nHD, nHA, log D, log S and log P. The bioavailability radar plot is a crucial visual tool that shows how well a compound fits with important drug-likeness properties by analysing six major properties (lipophilicity (LIPO): 0.7 < log P < 5.0, SIZE: 150 g mol−1 < MW < 500 g mol−1, polarity (POLAR): 20 Å2 < TPSA < 130 Å2, insolubility (INSOLU): 0 < log S < 6, insaturation (INSATU): 0.25 < fraction Csp3 < 1, and flexibility (FLEX): 0 < number of rotatable bonds < 9).34,39–41 Here, the bioavailability radar analysis was employed to evaluate the oral drug-likeness of the two potent compounds 3p and 3n, alongside the standard drug ciprofloxacin (Fig. 14). This result indicates that both potent compounds, 3p and 3n, displayed radar plots closely aligned with these recommended ranges. This suggests a comparatively favourable predicted oral drug-likeness profile. For both potent compounds, minor deviations were observed for the insaturation parameter. Both compounds marginally surpassed the ideal range. However, their remaining physicochemical attributes remained well within acceptable limits. In contrast, the standard antibacterial drug ciprofloxacin fell outside the optimal boundaries for polarity. Bioavailability radar of the potent compounds 3p, 3n and standard drug ciprofloxacin. ADME property prediction The ADME profiles of two potent compounds, 3p and 3n, alongwith the standard drug ciprofloxacin were examined using ADMETlab 3.0 and SwissADME to assess their suitability as drug-like candidates (Table 6). The predicted Caco-2 permeability values of 3p (−5.18 log units) and 3n (−5.24 log units) fall just below the recommended limit (≥ −5.15 log unit). These values indicate limited predicted passive permeability. Although these values suggest limited passive transport, they remain noticeably better than ciprofloxacin (−5.86 log unit). Their MDCK permeability values were −4.69 and −4.76, respectively. Both 3p and 3n were predicted to have low GI absorption, with HIA values of 0.06, indicating that intestinal absorption may represent a potential limitation. Neither 3p nor 3n was predicted to act as a P-gp substrate, which is potentially relevant for further evaluation because efflux-mediated loss often compromises intracellular drug levels. However, both compounds showed high predicted P-gp inhibition probabilities (0.86 for 3p and 0.98 for 3n), representing a potential transporter-related liability. The plasma protein binding values for 3p and 3n (∼79%) remain comfortably within acceptable limits, suggesting, based on the computational model, a potentially moderate balance between predicted free and protein-bound fractions. Their unbound fractions (14.4–14.5%) are considerably higher than standard drug. Both compounds were predicted to have negligible BBB permeability, while their predicted VDss values were −0.36 and −0.47 L kg−1 for 3p and 3n, respectively. These predictions provide preliminary information on possible distribution behaviour. Table 6Computationally predicted ADME properties of compounds 3p, 3n and ciprofloxacin using ADMETlab 3.0 and SwissADME web toolsADMET properties3p3nCiprofloxacinRecommended limit Absorption Caco-2 permeability−5.18−5.24−5.86≥ −5.15 log unitMDCK permeability−4.69−4.76−5.22≤20 × 10−6 cm s−1P-gp-inhibitor0.860.9800 to 0.5P-gp-substrate000.980 to 0.5HIA0.060.060.0020 to 1GI absorptionLowLowHighHigh/low Distribution PPB79.3279.2025.52≤90%BBB000.001<0.5VDss−0.36−0.470.260.04 to 20 L kg−1Fu14.4414.4955.51≥20% Metabolism CYP1A2 inhibitor0.420.1000 to 0.5CYP1A2 substrate110.0020 to 0.5CYP2C19 inhibitor0.020.0200 to 0.5CYP2C19 substrate0.630.9500 to 0.5CYP2C9 inhibitor0.840.6600 to 0.5CYP2C9 substrate0.880.9800 to 0.5CYP2D6 inhibitor0.060.6200 to 0.5CYP2D6 substrate0000 to 0.5CYP3A4 inhibitor0.970.9500 to 0.5CYP3A4 substrate000.0230 to 0.5CYP2B6 inhibitor0000 to 0.5CYP2B6 substrate0000 to 0.5CYP2C8 inhibitor0.010.0400 to 0.5 Excretion CLplasma0.890.603.315 to 15 mL min−1 kg−1 T 1/2 1.51.41.56>4 h Computationally predicted ADME properties of compounds 3p, 3n and ciprofloxacin using ADMETlab 3.0 and SwissADME web tools The CYP interaction profiles revealed several potential metabolic liabilities for the two potent compounds. Both 3p and 3n are predicted to be substrates of CYP1A2, CYP2C9, and CYP2C19, with relatively high probability scores. They also showed potential inhibitory effects on several CYP isoenzymes, particularly CYP2C9 and CYP3A4, with probability values close to 1. Compound 3n additionally showed a relatively high predicted CYP2D6 inhibition probability (0.62). These predicted CYP interactions indicate potential enzyme-mediated drug–drug interactions liabilities. These possibilities require experimental enzymatic and pharmacokinetic validation. The predicted plasma clearance values of 3p (0.89 mL min−1 kg−1) and 3n (0.60 mL min−1 kg−1) fall below the recommended range (5–15 mL min−1 kg−1), suggesting slow systemic clearance. Their half-lives (1.4–1.5 h) are shorter but remain within a workable range for compounds intended for short-duration exposure. Overall, 3p and 3n possess several physicochemical characteristics within commonly used drug-likeness ranges. However, the ADME predictions also indicate important pharmacokinetic limitations. These include low GI absorption, limited Caco-2 permeability, high P-gp inhibition probabilities, multiple CYP interaction liabilities, low predicted plasma clearance, and relatively short predicted half-lives. Consequently, these computational results should be regarded as preliminary, hypothesis-generating information and not as evidence of suitability for oral drug development. Experimental permeability, transporter, CYP, metabolic-stability and in vivo pharmacokinetic studies are required to establish the actual pharmacokinetic behaviour of these compounds. Toxicity property prediction As represented in Table 7, the toxicity properties of the potent compounds 3p and 3n, along with the reference ciprofloxacin were evaluated using ProTox 3.0 and pkCSM web tools.41–43 The computational toxicity predictions for compounds 3p and 3n indicated a mixed toxicity profile when compared with the reference drug ciprofloxacin. Compound 3p and the standard drug ciprofloxacin were non-mutagenic in the Ames test, but compound 3n showed a positive Ames response suggesting a potential structural alert in the latter. Their predicted maximum tolerated doses were below the recommended threshold, indicating moderate dosing constraints relative to ciprofloxacin. None of the tested compounds showed hERG I inhibition. Only compound 3n presented a possible hERG II interaction. This represents a potential liability requiring further investigation. Both potent compounds exhibited hepatotoxicity, whereas they were free from skin sensitization alerts. The predicted LD50 values were found around 1500 mg kg−1 with toxicity class 4 (Fig. 15), which falls within an acceptable range for early-stage candidates. Importantly, both potent compounds were predicted to be non-cytotoxic and inactive against phosphoprotein p53, which is comparable to the standard drug. Table 7Toxicity properties of the most active compounds 3p and 3n in comparison with standard drug ciprofloxacin using ProTox 3.0 and pkCSM web toolsaToxicity properties3p3nCiprofloxacinRecommended limitAmes toxicityNoYesYesNoMax. tolerated dose (human)−0.16−0.0810.168≥1.0 log mg kg−1 day−1hERG I inhibitorNoNoNoNohERG II inhibitorNoYesNoNoHepatotoxicityYesYesYesNoSkin sensitisationNoNoNoNoLD50150015002000≥2000 mg kg−1Toxicity class444≥4CytotoxicityInactive (0.52)Inactive (0.52)Inactive (0.92)InactivePhosphoprotein (tumor suppressor) p53Inactive (0.75)Inactive (0.75)Inactive (0.99)InactiveaAmes = Ames test for mutagenicity, hERG I = human ether-à-go-go-related gene channel 1, hERG II = human ether-à-go-go-related gene channel 2, LD50 = lethal dose for 50% of the test population, phosphoprotein p53 = tumor suppressor protein p53 (phosphorylated form). Toxicity properties of the most active compounds 3p and 3n in comparison with standard drug ciprofloxacin using ProTox 3.0 and pkCSM web toolsa Ames = Ames test for mutagenicity, hERG I = human ether-à-go-go-related gene channel 1, hERG II = human ether-à-go-go-related gene channel 2, LD50 = lethal dose for 50% of the test population, phosphoprotein p53 = tumor suppressor protein p53 (phosphorylated form). Predicted LD50 and classes of toxicity of two potent compounds 3p, 3n, and standard drug ciprofloxacin. Conclusion In conclusion, eighteen novel lawsone-based highly substituted benzopyran derivatives were successfully synthesized in high yields (62–94%) under mild conditions using a Michael addition reaction. The structures of the synthesized compounds were confirmed by 1H NMR, 13C NMR, FTIR and HRMS analyses. The relative configuration was assigned by ROESY spectra and further supported by CREST analysis. The present study describes the synthesis of a library of lawsone-based highly substituted benzopyran derivatives and their preliminary in vitro antibacterial evaluation against E. coli MTCC 614 and S. aureus MTCC 7443. Among the tested compounds, 3p exhibited the most promising antibacterial activity (ZI: 19 mm, 17 mm; MIC: 6.25 µg mL−1, 12.5 µg mL−1), comparable to ciprofloxacin. Molecular docking studies further suggested favourable interactions of selected compounds with bacterial DNA gyrase (−9.3 kcal mol−1 for E. coli, −8.2 kcal mol−1 for S. aureus), thereby providing a potential molecular hypothesis for their activity. Additionally, compounds 3g, 3l, 3n, and 3o demonstrated notable antibacterial activity (ZI ≥ 17 mm, MIC ≤ 25 µg mL−1). Based on SAR insights and docking studies, these lawsone-based benzopyran derivatives show promising potential as antibacterial agents. Thus, we anticipate that this work will aid in the development of novel heterocyclic scaffolds, contributing to future antibacterial drug discovery to combat antibacterial resistance. Experimental section All reagents and solvents were purchased from commercial suppliers. DABCO, salicylaldehyde, trans-β-nitro styrene, triethylamine and lawsone were purchased from Sigma-Aldrich and used without further purification. The progress of the reaction was monitored by Thin Layer Chromatography (TLC) performed on silica gel aluminium plates and visualization was done by UV light. 1H NMR and 13C NMR spectrums were recorded at 400 MHz and 100 MHz respectively, with TMS as an internal standard. Chemical shifts (δ) are reported in parts per million (ppm), downfield from the internal standard (TMS, δ = 0.00 ppm) relative to DMSO-d6 (1H: δ = 2.5 ppm, 13C: δ = 39.52 ppm) as an internal reference. Coupling constants (J) are reported in hertz (Hz). Peak multiplicity is indicated as follows: s-singlet, d-doublet, t-triplet, q-quartet, m-multiplets, and dd-doublet of doublet. High-resolution mass spectra (HRMS) were recorded using the Bruker micro TOF-QII mass spectrometer model at the laboratory of IIT Bombay. Experimental procedure Experimental procedure for the synthesis of lawsone-based highly substituted benzopyrans derivatives 3a–r A mixture of substituted 2-phenyl-3-nitro-2H-chromene derivatives [1a–r, 1.0 mmol], 2-hydroxy-1,4-naphthoquinone(lawsone) [2, 1.0 mmol], and Et3N (1.0 mmol) was taken in a clean, oven-dried seal tube, along with solvent toluene. This mixture was stirred at room temperature for 45 minutes. The progress of the reaction was monitored by using the TLC. After the completion of the reaction a single UV-active spot was observed. The reaction mixture was diluted with water upon completion, and the product was extracted with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4, and evaporated under reduced pressure. The impure product was then refined via standard silica gel (100–200 mesh) column chromatography, employing a mixture of ethyl acetate and hexane, generating the desired lawsone-based benzopyran derivatives 3a–r with a good to excellent yields (62–94%). 2-Hydroxy-3-(3-nitro-2-phenylchroman-4-yl)naphthalene-1,4-dione (3a) Orange–red solid (yield = 92%); M.P. = 200 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.06–8.01 (m, 2H), 7.89–7.80 (m, 2H), 7.43–7.36 (m, 5H), 7.23–7.15 (m, 2H), 7.05 (d, J = 7.6 Hz, 1H), 6.95–6.93 (t, J = 7.6 Hz, 1H), 5.96 (s, 1H), 5.68 (s, 1H), 5.01 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.7, 181.4, 157.7, 153.6, 135.9, 134.8, 133.3, 132.2, 130.2, 128.5, 128.4 (2C), 128.3, 127.6, 126.1, 125.8, 125.7 (2C), 121.8, 121.7, 120.8, 116.5, 87.5, 74.6, 33.7; IR (ν, cm−1): 3340, 2360, 1644, 1547, 1373, 1229; HRMS (ESI) calculated for C25H17NO6 [M + H]+ 428.1180 found 428.1126. 2-Hydroxy-3-(8-methoxy-3-nitro-2-phenylchroman-4-yl)naphthalene-1,4-dione (3b) Reddish orange solid (yield = 89%); M.P. = 192 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.02–7.78 (m, 5H), 7.41–7.38 (m, 5H), 6.89–6.82 (m, 2H), 6.71–6.69 (m, 1H), 5.92 (s, 1H), 5.65 (s, 1H), 5.00 (s, 1H), 3.80 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 184.0, 182.0, 147.9, 143.2, 135.9, 134.8, 133.2, 132.3, 130.2, 128.6, 128.5 (2C), 126.1, 125.8 (2C), 122.4, 121.3, 120.8, 119.7, 111.0, 110.1, 87.7, 74.7, 55.6, 33.8; IR (ν, cm−1): 3325, 2358, 1644, 1649, 1481, 1371, 1215, 1028; HRMS (ESI) calculated for C26H19NO7 [M + H]+ 458.1280, found 458.1228. 2-(6-Chloro-3-nitro-2-phenylchroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3c) Yellowish red solid (yield = 75%); M.P. = 202 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 7.97 (t, J = 6.8 Hz, 2H), 7.81–7.75 (m, 2H), 7.38–7.32 (m, 5H), 7.21–7.18 (m, 2H), 7.03 (d, J = 8.8 Hz, 1H), 5.90 (s, 1H), 5.54 (s, 1H), 4.92 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 182.5, 182.3, 153.1, 136.1, 135.1, 133.4, 133.2, 130.9, 129.1, 128.9 (3C), 128.3, 127.9, 126.5, 126.1 (3C), 125.8, 124.9, 120.3, 118.6, 87.9, 75.2, 34.5; IR (ν, cm−1): 3317, 1653, 1549, 1480, 1369; HRMS (ESI) calculated for C25H16ClNO6 [M + H]+ 462.0780, found 462.0740. 2-(6-Bromo-3-nitro-2-phenylchroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3d) Orange solid (yield = 77%); M.P. = 205 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 7.16–6.90 (m, 4H), 6.57–6.48 (m, 7H), 6.18–6.16 (m, 1H), 5.14 (s, 1H), 4.71 (s, 1H), 4.13 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 181.6, 181.4, 159.4, 152.2, 134.7, 133.6, 132.0, 131.8, 129.7, 129.6, 129.2, 127.6, 127.5 (2C), 127.0, 125.0, 124.7 (2C), 124.3, 118.7, 117.7, 112.2, 86.8, 73.8, 33.0; IR (ν, cm−1): 3340, 2363, 1686, 1547, 1479, 1366, 1230; HRMS (ESI) calculated for C25H16BrNO6 [M + H]+ 506.0280, found 506.0216. 2-(6,8-Dichloro-3-nitro-2-phenylchroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3e) Reddish orange solid (yield = 69%); M.P. = 192 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.03 (t, J = 7.2 Hz, 2H), 7.90–7.81 (m, 2H), 7.53 (d, J = 2.4 Hz, 1H), 7.50 (d, J = 7.2 Hz, 2H), 7.45–7.38 (m, 3H), 7.34 (d, J = 2.0 Hz, 1H) 5.87 (s, 1H), 5.63 (s, 1H), 4.99 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.3, 181.4, 158.0, 148.4, 135.0, 134.7, 133.2, 132.4, 130.3, 128.7, 128.5 (2C), 127.5, 127.1, 126.1, 125.7, 125.5 (2C), 125.3, 125.1, 121.1, 119.7, 86.3, 74.7, 34.4; IR (ν, cm−1): 3294, 2361, 1681, 1638, 1558, 1367, 1278; HRMS (ESI) calculated for C25H15Cl2NO6 [M + H]+ 496.0380, found 496.0356, [M + H + 2]+ 498.0334 and [M + H + 4]+ 500.0325. 2-(6,8-Dibromo-3-nitro-2-phenylchroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3f) Brick red solid (yield = 73%); M.P. = 199 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 7.98–7.39 (m, 11H), 5.86 (s, 1H), 5.61 (s, 1H), 4.98 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.3, 181.5, 158.2, 149.8, 135.1, 134.8, 134.6, 133.2, 132.8, 132.5, 130.5, 130.4, 128.7, 128.6 (2C), 126.1, 125.8, 125.6 (2C), 119.8, 113.1, 110.9, 86.5, 74.9, 34.5; IR (ν, cm−1): 3303, 2359, 1680, 1640, 1557, 1444, 1368, 1279; HRMS (ESI) calculated for C25H15Br2NO6 [M + H]+ 585.9280, found 585.9295. 2-(8-Bromo-6-chloro-3-nitro-2-phenylchroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3g) Yellowish orange solid (yield = 71%); M.P. = 198 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 7.99 (d, J = 7.2 Hz, 2H), 7.82 (t, J = 7.2 Hz, 1H), 7.79–7.73 (m, 1H), 7.59 (d, J = 2.1 Hz, 1H), 7.52 (d, J = 7.2 Hz, 2H), 7.44–7.34 (m, 3H), 7.30 (d, J = 2.4 Hz, 1H), 6.01 (s, 1H), 5.61 (s, 1H), 5.02 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 182.4, 182.3, 149.4, 135.3, 134.6, 133.3, 133.0, 132.8, 130.6, 130.0, 128.7, 128.6 (2C), 127.6, 126.0 (2C), 125.7, 125.6 (2C), 119.4, 111.1, 110.5, 87.2, 75.1, 34.8; IR (ν, cm−1): 3305, 2360, 1644, 1549, 1458, 1367, 1241; HRMS (ESI) calculated for C25H15BrClNO6 [M + H]+ 539.9880, found 539.9823 and [M + H + 2]+ 541.9809. 2-(6-Bromo-8-methoxy-3-nitro-2-phenylchroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3h) Reddish orange solid (yield = 88%); M.P. = 189 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.02 (t, J = 8.0 Hz, 2H), 7.88–7.79 (m, 2H), 7.42–7.36 (m, 6H), 7.06 (d, J = 1.6 Hz, 1H), 6.97 (s, 1H), 5.87 (s, 1H), 5.59 (s, 1H), 4.96 (s, 1H), 3.85 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.2, 181.7, 158.6, 148.8, 142.6, 135.6, 134.6, 133.0, 132.5, 130.4, 128.6, 128.4 (2C), 126.0, 126.0, 125.7 (3C), 124.5, 122.0, 119.9, 113.1, 112.7, 87.3, 74.6, 56.0, 33.9; IR (ν, cm−1): 3169, 2920, 2358, 1650, 1555, 1484, 1376; HRMS (ESI) calculated for C26H18BrNO7 [M + H]+ 536.0380 found 536.0327 and [M + H + 2]+ 538.0312. 2-(6-Chloro-2-(4-chlorophenyl)-3-nitrochroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3i) Light orange solid (yield = 69%); M.P. = 217 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.23 (t, J = 7.6 Hz, 2H), 8.10–8.00 (m, 2H), 7.70 (s, 5H), 7.49 (d, J = 2.0 Hz, 1H), 7.45 (dd, J12 = 2.4 Hz, J13 = 8.8 Hz, 1H), 7.30 (d, J = 8.8 Hz, 1H), 6.12 (s, 1H), 5.81 (s, 1H), 5.19 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.3, 181.7, 158.5, 152.4, 134.7, 134.6, 133.2, 133.1, 132.5, 130.4, 128.5 (2C), 127.9, 127.6 (2C), 127.5, 126.1, 125.7, 125.5, 124.1, 119.9, 118.2, 87.1, 74.0, 34.0; IR (ν, cm−1): 3295, 2358, 1644, 1549, 1481, 1371, 1215, 1028; HRMS (ESI) calculated for C25H15Cl2NO6 [M + H]+ 496.0380, found 496.0332 and [M + H + 2]+ 498.0310. 2-(6-Bromo-2-(4-chlorophenyl)-3-nitrochroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3j) Reddish orange solid (yield = 68%); M.P. = 243 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.01–7.96 (m, 2H), 7.85–7.77 (m, 2H), 7.44–7.31 (m, 6H), 6.99 (d, J = 8.0 Hz, 1H), 5.80 (s, 1H), 5.57 (s, 1H), 4.93 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.7, 181.3, 157.5, 152.9, 134.8, 134.6, 133.4, 133.3, 132.3, 130.8, 130.5, 130.3, 128.6 (2C), 127.7 (2C), 126.2, 125.8, 124.2, 120.1, 118.7, 113.4, 86.7, 73.9, 33.9; IR (ν, cm−1): 3303, 2360, 1641, 1550, 1369, 1263; HRMS (ESI) calculated for C25H15BrClNO6 [M + H]+ 538.98, found 539.9837, [M + H + 2]+, 541.9818 and [M + H + 4]+ 543.9805. 2-(6,8-Dibromo-2-(4-chlorophenyl)-3-nitrochroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3k) Brick red solid (yield = 64%); M.P. = 250 °C 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.05–8.01 (m, 2H), 7.90–7.81 (m, 2H), 7.74 (d, J = 2.0 Hz, 1H), 7.58–7.49 (m, 5H), 5.89 (s, 1H), 5.66 (s, 1H), 5.02 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.4, 181.5, 158.1, 149.6, 134.9, 134.2, 133.5, 133.4, 132.9, 132.4, 130.6, 130.4, 128.7 (2C), 127.5 (2C), 126.2, 125.9, 125.7, 119.7, 113.3, 110.8, 86.3, 74.3, 34.6; IR (ν, cm−1): 3261, 2359, 1640, 1551, 1365, 1276; HRMS (ESI) calculated for C25H14Br2ClNO6 [M + H]+ 617.8980, found 617.8938, [M + H + 2]+ 619.8919, [M + H + 4]+ 621.8900, and [M + H + 6]+ 623.8886. 2-(8-Bromo-6-chloro-2-(4-chlorophenyl)-3-nitrochroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3l) Orange solid (yield = 62%); M.P. = 254 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.02–7.99 (m, 2H), 7.88–7.77 (m, 2H), 7.64 (d, J = 2.0 Hz, 1H), 7.57–7.51 (m, 4H), 7.34 (s, 1H), 5.95 (s, 1H), 5.62 (s, 1H), 5.00 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 182.6, 181.9, 149.1, 134.6, 134.2, 133.3, 132.9, 132.8, 130.4, 130.0, 128.6 (3C), 127.6, 127.4 (2C), 125.9, 125.7, 125.6 (2C), 119.3, 110.3, 86.6, 74.4, 34.6; IR (ν, cm−1): 3271, 2357, 1676, 1639, 1552, 1455, 1362; HRMS (ESI) calculated for C25H14BrCl2NO6 [M + H]+ 573.9480 found 573.9448, [M + H + 2]+ 575.9422, [M + H + 4]+ 577.9406, and [M + H+6]+ 579.9381. 2-Hydroxy-3-(8-methoxy-2-(4-methoxyphenyl)-3-nitrochroman-4-yl)naphthalene-1,4-dione (3m) Reddish orange solid (yield = 94%); M.P. = 172 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.05–7.99 (m, 2H), 7.89–7.80 (m, 3H), 7.31 (d, J = 6.8 Hz, 2H), 6.96 (d, J = 8.4 Hz, 2H), 6.90–6.82 (m, 2H), 6.70 (d, J = 8.0 Hz, 1H) 5.84 (s, 1H), 5.62 (s, 1H), 4.98 (s, 1H), 3.81 (s, 3H), 3.76 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.7, 181.2, 159.3, 157.4, 147.9, 143.1, 134.8, 133.3, 132.1, 130.1, 127.7, 127.1 (2C), 126.1, 125.7, 122.1, 121.2, 120.9, 119.6, 113.8 (2C), 110.1, 87.3, 74.4, 55.5, 55.1, 33.5; IR (ν, cm−1): 3358, 2867, 1642, 1548, 1368, 1248, 1028; HRMS (ESI) calculated for C27H21NO8 [M + H]+ 488.1380 found 488.1337. 2-(6-Chloro-2-(4-methoxyphenyl)-3-nitrochroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3n) Reddish orange solid (yield = 82%); M.P. = 153 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.09–8.04(m,2H), 7.93–7.85 (m, 2H), 7.36 (d, J = 8.8 Hz, 2H), 7.33–7.32 (m, 1H), 7.27(dd, J12 = 2.8 Hz, J13 = 8.8 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 6.99(d, 8.8 Hz, 2H), 5.84 (s, 1H), 5.60 (s, 1H), 4.98 (s, 1H), 3.80 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.7, 181.3, 159.4, 157.3, 152.6, 134.8, 133.3, 132.3, 130.4, 127.9, 127.6, 127.4, 127.1 (2C), 126.1, 125.8, 125.3, 123.8, 120.1, 118.2, 113.9 (2C), 86.9, 74.5, 55.2, 33.8; IR (ν, cm−1): 3312, 2361, 1644, 1549, 1369, 1234; HRMS (ESI) calculated for C26H18ClNO7 [M + H]+ 492.0880, found 492.0839 and [M + H + 2]+ 494.0817. 2-(6-Bromo-2-(4-methoxyphenyl)-3-nitrochroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3o) Yellowish orange solid (yield = 88%); M.P. = 185 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.04–8.00 (m, 2H), 7.89–7.82 (m, 2H), 7.39–7.31 (m, 4H), 7.02–6.94 (m, 3H), 5.81 (s, 1H), 5.55 (s, 1H), 4.95 (s, 1H), 3.76 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.4, 181.4, 159.3, 153.1, 134.7, 133.1, 132.4, 130.7, 130.3, 127.3, 127.0 (3C), 126.0, 125.7, 124.3, 120.0, 118.5, 113.8 (3C), 113.0, 86.9, 74.3, 55.1, 33.7; IR (ν, cm−1): 3307, 2921, 2360, 1439, 1555, 1366; HRMS (ESI) calculated for C26H18BrNO7 [M + H]+ 536.0380 found 536.0328 and [M + H + 2]+ 538.0314. 2-(6,8-Dichloro-2-(4-methoxyphenyl)-3-nitrochroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3p) Reddish orange solid (yield = 79%); M.P. = 182 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.03 (t, J = 7.6 Hz, 2H), 7.90–7.80 (m, 2H), 7.52 (s, 1H), 7.40 (dd, J12 = 2.0 Hz, J13 = 8.8 Hz, 2H), 7.32 (d, J = 2.4 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 5.82 (s, 1H), 5.59 (s, 1H), 4.99 (s, 1H), 3.77 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.3, 181.4, 170.5, 159.4, 157.7, 148.5, 134.7, 133.2, 132.4, 130.3, 127.4, 127.1, 126.9 (2C), 126.1, 125.7, 125.2, 125.0, 121.1, 119.7, 113.9 (2C), 86.3, 74.6, 51.1, 34.3; IR (ν, cm−1): 3306, 2359, 1644, 1550, 1458, 1366; HRMS (ESI) calculated for C26H17Cl2NO7 [M + H]+ 526.0480 found 526.0446 and [M + H + 2]+ 528.0416. 2-(6,8-Dibromo-2-(4-methoxyphenyl)-3-nitrochroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3q) Reddish orange solid (yield = 80%); M.P. = 199 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.03 (t, J = 7.2 Hz, 2H), 7.90–7.80 (m, 2H), 7.73 (d, J = 2.4 Hz, 1H), 7.47–7.40 (m, 2H), 6.98 (d, J = 8.8 Hz, 2H), 5.80 (s, 1H), 5.58 (s, 1H), 4.97 (s, 1H), 3.76 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.3, 181.3, 159.4, 157.7, 149.7, 134.7, 133.2, 132.7, 132.3, 130.4, 130.3, 126.8 (3C), 126.1, 125.7, 125.5, 119.7, 113.9 (2C), 112.9, 110.7, 86.3, 74.6, 55.1, 34.4; IR (ν, cm−1): 3305, 2349, 1640, 1552, 1455, 1367, 1028; HRMS (ESI) calculated for C26H17Br2NO7 [M + H]+ 613.9480 found 613.9435, [M + H + 2]+ 615.9412 and [M + H + 4]+ 617.9400. 2-(8-Bromo-6-chloro-2-(4-methoxyphenyl)-3-nitrochroman-4-yl)-3-hydroxynaphthalene-1,4-dione (3r) Reddish orange solid (yield = 77%); M.P. = 189 °C, 1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.04 (t, J = 7.6 Hz 2H), 7.90–7.81 (m, 2H), 7.63 (d, J = 2.0 Hz, 1H), 7.43–7.38 (m, 3H), 6.99 (d, J = 8.8 Hz, 2H), 5.81 (s, 1H), 5.60 (s, 1H), 4.98 (s, 1H), 3.77 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) 183.4, 181.3, 159.4, 157.6, 149.3, 134.7, 133.3, 132.3, 130.3, 130.2, 127.7, 126.8 (3C), 126.1, 125.7, 125.5, 125.0, 119.8, 113.9 (2C), 110.4, 86.3, 74.7, 55.1, 34.4; IR (ν, cm−1): 3307, 2353, 1641, 1550, 1452, 1364, 1029; HRMS (ESI) calculated for C26H17BrClNO7 [M + H]+ 569.9980 found 569.9942, [M + H + 2]+ 571.9924 and [M + H + 4]+ 573.9909. CREST analysis To explore the low-energy conformers of Structure-A to Structure-H, we used the CREST program.44 First, the starting geometries of the eight configurations were optimized in the gas phase using the B3LYP/6-311++G(d,p) level of theory. We then used these optimized structures as the starting point for a CREST search using ‘‘GFN2-xTB” method. We found 6, 8, 6, 6, 5, 8 3, 4 numbers of conformers for Structure-A, B, C, D, E, F, G and H respectively. Next, these conformers were reoptimized in the gas phase using Gaussian 16 at the B3LYP/6-311++G(d,p) level of theory. We also ran frequency analyses at this same level to confirm they were true energy minima having zero imaginary frequency. In the end, this process successfully identified the different conformers of the eight possible configurations of the compound 3a as well as the most probable configuration of compound 3a. Molecular docking studies of compound 3a–r against bacterial DNA gyrase of E. coli and S. aureus All the synthesized derivatives 3a–r were carefully drawn with proper stereochemistry and the 2D structures were converted to optimized 3D structures. Molecular docking studies were conducted using Autodock Tools version 4.2.0. The host proteins, including the bacterial DNA gyrase inhibitors for Gram-negative bacterial protein E. coli (PDB ID: 1KZN) and Gram-positive bacterial protein S. aureus (PDB ID: 3G75), were downloaded and retrieved from the RCSB Protein Data Bank (https://www.rcsb.org/). Before docking the complex, water molecules and other hetero-atoms were removed from these host protein structures using PyMOL (https://www.pymol.org/). Also, polar hydrogen bonds were added, and a grid box was set to 60 × 60 × 60 for the xyz axes (covering ligand binding pocket). 0.375 Å is the grid space for 100 genetic algorithm runs. The two programs, ‘autodock’ and ‘autogrid’, were used to determine the binding affinity scores for the ligand–protein interaction region of the respective GyrB structures. The 2D structures of ligand–receptor interactions were visualized using PyMOL 3.1 and BIOVIA Discovery Studio v 2017. In vitro antibacterial evaluation of compound 3a–r against E. coli and S. aureus The antibacterial assay of the synthesized compounds 3a–r was evaluated against Escherichia coli MTCC 614 (Gram-negative) and Staphylococcus aureus MTCC 7443 (Gram-positive). Fresh bacterial cultures were used to prepare the inoculum, which was standardized to a 0.5 McFarland turbidity, corresponding to approximately 1.5 × 108 CFU mL−1. For the agar-well diffusion assay, 20–25 mL of sterilized Mueller–Hinton agar was poured into sterile Petri plates and allowed to solidify. The standardized bacterial suspension was uniformly spread over the agar surface, followed by the preparation of 6 mm-diameter wells using a sterile cork borer. The synthesized compounds were dissolved in DMSO, and 80 µL of each test solution at 100 µg mL−1 was added to the corresponding wells. Ciprofloxacin was used as the positive control, and DMSO and untreated bacterial cultures were used as the negative controls. The plates were incubated at 37 °C for 24 h, after which the diameter of the inhibition zones was measured in millimeters (mm). Furthermore, for MIC determination, the compounds were evaluated at concentrations of 6.25, 12.5, 25, 50, and 100 µg mL−1 using a serial dilution procedure in a 96-well microplate. The MIC was defined as the lowest concentration tested that prevented detectable bacterial growth under the experimental conditions, as determined using TTC. Each experiment was performed using three independent biological replicates, with technical replication for each experimental condition.45–48 ADMET studies The physicochemical, medicinal chemistry and ADME (Absorption, Distribution, Metabolism and Excretion) properties of two potent compounds 3p, 3n and standard drug ciprofloxacin were predicted by using web-based analytical tools, including SwissADME (https://www.swissadme.ch/; last accessed on 10th November 2025),49 ADMET lab 3.0 (https://admetlab3.scbdd.com/; last accessed on 10th November 2025)50 and Molsoft L.L.C (https://www.molsoft.com/mprop/; accessed on 10th November 2025).51 The toxicity properties were predicted by web-based softwares pkCSM (https://biosig.lab.uq.edu.au/pkcsm/; last accessed on 12th November 2025) and Pro Tox 3.0 (https://tox.charite.de/protox3/index.php?; last accessed on 12th November 2025).43 Author contributions Ananya Dash: conceptualization, investigation, methodology, formal analysis, data curation, writing – review & editing; Barsha Samanta: methodology, writing original draft, data-curation, writing – review & editing; Sonali Priyadarshini Parida: methodology, data-curation; Tapaswini Pati: writing – review & editing; Laxmipriya Dash: CREST software analysis, writing original draft; Bhabani Shankar Panda: ADMET evaluations, writing – review & editing; Chita Ranjan Sahoo: software, antibacterial studies; Seetaram Mohapatra: supervision, conceptualization, investigation, resources, funding acquisition, writing – review & editing. Conflicts of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Supplementary Material